This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
by Ahan Chakraborty
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
by Zacks Equity Research
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
GSKNegative Net Change PFENegative Net Change GILDNegative Net Change CVSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
by Ekta Bagri
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
NVSNegative Net Change MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
IOVA Stock Drops 6% on $350M Common Stock Offering
by Zacks Equity Research
Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline.
MRKNegative Net Change ANIPNegative Net Change CRMDNegative Net Change IOVANegative Net Change
biotechs medical
AMGN Up Almost 14% YTD: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs
RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?
by Zacks Equity Research
Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.
NVSNegative Net Change BMYNegative Net Change LLYNegative Net Change RNAPositive Net Change
biotechs medical pharmaceuticals
PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug
by Zacks Equity Research
Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.
INONegative Net Change CRMDNegative Net Change KNSAPositive Net Change PGENNegative Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
by Ekta Bagri
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY vs GSK: Which Biopharma Bigwig Has Better Prospects for Now?
by Ekta Bagri
Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.
GSKNegative Net Change BMYNegative Net Change
biotechnology biotechs medical pharmaceuticals
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
by Zacks Equity Research
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
GILDNegative Net Change CVSPositive Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
by Sundeep Ganoria
Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and future prospects.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
by Kanishka Das
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
VRTXNegative Net Change BEAMNegative Net Change NTLANo Net Change CRSPPositive Net Change
biotechs
RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study
by Zacks Equity Research
Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.
AMRNPositive Net Change RCKTNegative Net Change AKRONegative Net Change ALGSNegative Net Change
biotechs
FDA Extends Review Period of REGN's Submission for Eylea HD
by Zacks Equity Research
The FDA extends action dates for Regeneron's Eylea HD filings following inspection findings at Catalent Indiana. Nonetheless, Eylea HD remains available through vial administration.
REGNNegative Net Change NVOPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug
by Zacks Equity Research
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.
GSKNegative Net Change JAZZNegative Net Change ACADNegative Net Change
biotechs medical
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
by Zacks Equity Research
VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
by Zacks Equity Research
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
NVSNegative Net Change QGENNegative Net Change INCYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Does Cobenfy Have the Potential to Become a Top Drug for BMY?
by Ekta Bagri
Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.
BMYNegative Net Change ABBVNegative Net Change RVPHNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will EXEL's Share Repurchase Program Boost Value for Investors?
by Ekta Bagri
Exelixis repurchases shares for $796M, aiming to boost EPS and shareholder value through 2025.
REGNNegative Net Change NVSNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
by Zacks Equity Research
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
by Zacks Equity Research
REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
by Ahan Chakraborty
Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
CRMDNegative Net Change ZYMENegative Net Change KODNegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
by Zacks Equity Research
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
RHHBYNegative Net Change SRPTNegative Net Change ARWRNo Net Change
biotechs
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.
AMRNPositive Net Change ALLONegative Net Change AKRONegative Net Change ALGSNegative Net Change
biotechs earnings